
Medical Policy



Nonprofit corporations and independent licensees
of the Blue Cross and Blue Shield Association

Joint Medical Policies are a source for BCBSM and BCN medical policy information only. These documents are not to be used to determine benefits or reimbursement. Please reference the appropriate certificate or contract for benefit information. This policy may be updated and is therefore subject to change.

***Current Policy Effective Date: 5/1/22**
(See policy history boxes for previous effective dates)

Title: CT (Computed Tomography) Perfusion Imaging of the Brain

Description/Background

Perfusion imaging using computed tomography (CT) provides an assessment of cerebral blood flow that may assist in the identification of ischemic regions of the brain. This technology is proposed as a method to aid treatment decisions in patients being evaluated for acute ischemic stroke, subarachnoid hemorrhage, cerebral vasospasm, brain tumors, and head trauma.

ACUTE STROKE

The goal of acute stroke thrombolytic treatment is to rescue the ischemic penumbra, an area of brain that surrounds the infarct core and is hypo-perfused but does not die quickly. Multimodal computed tomography (CT) and magnetic resonance imaging (MRI) can be used to assess the cerebral parenchyma, vasculature, and tissue viability in the acute ischemic stroke setting and are used to detect ischemic tissue and exclude hemorrhage and other conditions that mimic acute cerebral ischemia.

Non-contrast CT is used to rule out intracranial hemorrhage, tumor, or infection. Magnetic resonance diffusion-weighted imaging (DWI) demonstrates acute infarction, and a gradient-recalled echo (GRE) sequence excludes intracerebral hemorrhage.

Computed tomography angiography (CTA) and magnetic resonance angiography (MRA) are used to evaluate intra- and extra-cranial vasculature to detect the vascular occlusion and potentially guide therapy (e.g., intravenous thrombolytics, or intra-arterial or mechanical thrombolysis).

The approved thrombolytic therapy, an intravenous tissue plasminogen activator (tPA), requires only a non-contrast CT scan to exclude the presence of hemorrhage (a contraindication to the use of the drug). Current guidelines are to administer tPA within the first 3 hours after an ischemic event, preceded by a CT scan. Many patients, however, do not present within the 3-hour window, and thrombolysis carries a risk of intracranial hemorrhage. Thus, more sophisticated imaging may be needed to select the proper use of intra-arterial thrombolysis or

mechanical thrombectomy in patients who present more than 3 hours after an ischemic stroke. Perfusion imaging is also being evaluated in the management of other neurologic conditions, such as subarachnoid hemorrhage and head trauma.

The potential utility of perfusion imaging of acute stroke is as follows:

- Identification of brain regions with extremely low cerebral blood flow, which represents the core
- Identification of patients with at-risk brain regions (acutely ischemic but viable penumbra) that may be salvageable with successful intra-arterial thrombolysis beyond the standard 3-hour window
- Triage of patients with at-risk brain regions to other available therapies, such as induced hypertension or mechanical clot retrieval
- Decisions regarding intensive monitoring of patients with large abnormally perfused brain regions
- Biologically-based management of patients who awaken with a stroke for which the precise time of onset is unknown

Additional potential uses of perfusion CT (CTP) in acute stroke may include the following:

- Detection and differential diagnosis (e.g., excluding stroke mimics such as transient ischemic attack, complex migraine, seizure, conversion disorders, hypoglycemia, brain tumors)
- Determination of stroke subtype
- Determination of stroke extent including additional vascular territories at risk
- Identification of patients at high early risk for stroke following transient ischemic attack
- Determining the need for blood pressure management
- Establishing prognosis

Similar information can be provided by CT and MRI in terms of infarct core and penumbra. However, multimodal CT has a short protocol time (5-6 min), and because it can be performed with any modern CT equipment, is more widely available in the emergency department setting. CT perfusion is performed by capturing images as an iodinated contrast agent bolus passes through the cerebral circulation and accumulates in the cerebral tissues. (Older perfusion methodologies such as single-photon emission CT [SPECT] and xenon-enhanced CT [XeCT] scanning use a diffusible tracer.) The quantitative perfusion parameters are calculated from density changes for each pixel over time with commercially available deconvolution-based software, in which cerebral blood flow (CBF) is equal to regional cerebral blood volume (CBV) divided by mean transit time (MTT). CT angiography/CT perfusion requires ionizing radiation and iodinated contrast. It is estimated that a typical CT perfusion deposits a slightly greater radiation dose than a routine unenhanced head CT (≈ 3.3 mSv).

SUBARACHNOID HEMORRHAGE AND CEREBRAL VASOSPASM

Cerebral vasospasm is one of the major causes of morbidity and mortality following aneurysmal subarachnoid hemorrhage (ASAH) in patients who survive the initial hemorrhage and can be seen in about two thirds of patients with ASAH. The typical onset of cerebral vasospasm occurs at 3 to 5 days after hemorrhage, with maximal narrowing on digital subtraction angiography at 5-14 days. Currently, the diagnosis of vasospasm and management decisions rely on clinical examination, transcranial Doppler sonography, and digital subtraction angiography. Although symptomatic vasospasm affects 20% to 30% of patients with ASAH, not all patients with angiographic vasospasm manifest clinical symptoms, and the symptoms can be nonspecific. In addition, patients do not always have both clinical and imaging findings of vasospasm. Due to

these limitations, more accurate and reliable methods to detect cerebral vasospasm are being investigated.

BRAIN TUMORS

The current standard for tumor grading is histopathologic assessment of tissue. Limitations of histologic assessment include sampling error due to regional heterogeneity and interobserver variation. These limitations can result in inaccurate classification and grading of gliomas. Because malignant brain tumors are characterized by neovascularity and increased angiogenic activity, perfusion imaging has been proposed as a method to assess tumor grade and prognosis. In addition, perfusion imaging can be repeated and may help to assess the evolution of tumors and the treatment response. Traditionally, perfusion imaging of brain tumors has been performed with MRI, which can estimate tumor blood volume, blood flow, and permeability. More recently, CT perfusion has been investigated for glioma grading. Potential advantages, compared with MR perfusion, include the wider availability, faster scanning times, and lower cost. CT perfusion may also be useful in distinguishing recurrent tumor from radiation necrosis.

Regulatory Status:

Several post-processing software packages (e.g., Siemens' syngo® Perfusion-CT, GE Healthcare's CT Perfusion 4, Philips Medical System's Brain Perfusion Option) have been cleared for marketing by the U.S. Food and Drug Administration (FDA) through the 510(k) process for use with a CT system to perform perfusion imaging. The software is being distributed with new CT scanners. FDA product code: JAK

Medical Policy Statement

Computed tomography (CT)–based perfusion imaging may be considered established to select patients with stroke for mechanical embolectomy.

CT-based perfusion imaging of the brain is considered experimental/investigational for all other indications. It has not been scientifically demonstrated to improve patient clinical outcomes.

Inclusionary and Exclusionary Guidelines (Clinically based guidelines that may support individual consideration and pre-authorization decisions)

Inclusions

- Computed tomography (CT)–based perfusion imaging to select patients with stroke for mechanical embolectomy.

Exclusions

- CT-based perfusion imaging of the brain for all other indications not specified under the inclusions.

CPT/HCPCS Level II Codes *(Note: The inclusion of a code in this list is not a guarantee of coverage. Please refer to the medical policy statement to determine the status of a given procedure)*

Established codes:

0042T

Other codes (investigational, not medically necessary, etc.):

N/A

Rationale

Evidence reviews assess whether a medical test is clinically useful. A useful test provides information to make a clinical management decision that improves the net health outcome. That is, the balance of benefits and harms is better when the test is used to manage the condition than when another test or no test is used to manage the condition.

The first step in assessing a medical test is to formulate the clinical context and purpose of the test. The test must be technically reliable, clinically valid, and clinically useful for that purpose. Evidence reviews assess the evidence on whether a test is clinically valid and clinically useful. Technical reliability is outside the scope of these reviews, and credible information on technical reliability is available from other sources.

ACUTE STROKE

Clinical Context and Test Purpose

The purpose of computed tomography perfusion (CTP) imaging in patients with acute stroke who are being evaluated for thrombolysis is to guide treatment decisions.

The question addressed in this evidence review is: Does CTP improve the net health outcome of patients with stroke who are being evaluated for thrombolysis?

The following **PICOs** were used to select literature to inform this review.

Patients

The relevant population of interest is patients with acute stroke who are being evaluated for thrombolysis or mechanical embolectomy, and patients with acute stroke who are being evaluated for prognosis.

Interventions

The interventions of interest are CTP imaging.

Comparators

The comparator of interest is standard stroke management without CTP (non-contrast computed tomography [NCCT], computed tomography angiography [CTA]).

Outcomes

The outcomes of interest are function measured with the National Institutes of Health Stroke Scale (NIHSS) or modified Rankin Scale (mRS) scores following thrombolysis or mechanical embolectomy.

Study Selection Criteria

For the evaluation of CTP imaging, studies that meet the following eligibility criteria were considered:

- Reported on outcomes associated with the use of CTP to guide therapy decisions in a relevant patient population
- Patient/sample clinical characteristics were described
- Patient/sample selection criteria were described.

Clinically Valid

A test must detect the presence or absence of a condition, the risk of developing a condition in the future, or treatment response (beneficial or adverse).

Review of Evidence

No head-to-head randomized controlled trials (RCTs) were identified that directly compared CTP imaging-guided thrombolytic therapy vs. thrombolytic therapy guided by another imaging modality. Alternatively, the best available evidence assessing that comparison comes from a study by Bivard et al (2015) that compared the qualitative analysis of CTP imaging (n=366) to historical controls (n=396) selected for tissue plasminogen activator (tPA) based on clinical and NCCT information.² Patients selected for a tPA based on qualitative analysis of CTP imaging had higher odds of an excellent outcome (mRS score, 0-1; odds ratio [OR], 1.59, p=0.009) and lower mortality (OR=0.56, p=0.021) than historical controls. In addition, of patients treated with tPA, those who had a target mismatch by CTP imaging had significantly better outcomes than patients treated with tPA who did not (OR=13.8 for 3-month mRS score, ≤ 2). However, 83 (31%) of 269 untreated patients had target mismatch, and 56 (15%) of 366 treated patients had a large ischemic core. This observational study suggested that CTP imaging might identify those patients with acute stroke who are likely and unlikely to respond to thrombolysis. However, questions remain about whether CTP imaging is sufficiently reliable to select individual stroke patients for treatment.^{3,4}

Additionally, Burton et al (2015) reported on a meta-analysis of 13 small but generally good-quality studies (including 3 RCTs and 6 prospective cohort studies) that used CTP imaging and provided intravenous thrombolytic treatment (Tables 1 and 2).¹ The objectives of the studies included comparisons of thrombolytic agents and predictions of clinical outcomes.

Although relatively few patients received tPA based on CTP imaging results, the meta-analysis found rates of 90-day mortality, mRS scores ≤ 2 and in-hospital symptomatic intracranial hemorrhage rates (Table 2) that meta-analysis authors indicated “are comparable with those in studies that used other image modalities.” However, to definitively determine the clinical utility of CTP imaging, RCT’s are still needed that directly compare CTP imaging-guided thrombolytic therapy vs thrombolytic therapy guided by another imaging modality.

Table 1. Thrombolysis SR & M-A Characteristics

Study	Dates	Trials	Participants ¹	N (Range)	Design	Duration
-------	-------	--------	---------------------------	-----------	--------	----------

Burton (2015)	Search dates: 1946-2012;	13	Patients with acute ischemic stroke who underwent perfusion CT neuroimaging for thrombolytic therapy selection	557 (2-140)	RCT's (3), prospective cohorts (7), retrospective cohorts (3)	In hospital to 90 days
---------------	--------------------------	----	----------------------------------------------------------------------------------------------------------------	-------------	---------------------------------------------------------------	------------------------

CT: computed tomography; M-A: meta-analysis; RCT: randomized controlled trial; SR: systematic review.

Table 2. Results From Burton 2015 Systematic Review

Study		90-Day Mortality	mRS Score ≤ 2 at 90 Days	In-Hospital SICH
All patients	Total N	118	100	171
	Pooled Effect (95% CI)	10.0% (5.4%, 15.9%)	59.4% (38.2%, 78.9%)	3.6% (1.4%, 6.8%)
	I^2	0	73.1	0
Treated ≤ 3 hrs	Total N	95	47	94
	Pooled Effect (95% CI)	12.5% (6.7%, 19.7%)	42.5 (16.6%, 70.9%)	3.3% (0.7%, 7.7%)
	I^2	0	N/A	0
Treated >3 hrs	Total N	23	53	77
	Pooled effect (95% CI)	2.9% (0%, 12.7%)	69.9% (0%, 83.5%)	3.9% (0.8%, 9.2%)

CI: confidence interval; CT: computed tomography; mRS: modified Rankin Scale; NA: not available; SICH: symptomatic intracranial hemorrhage.

Another area of research is whether CTP imaging can help select ischemic stroke patients for thrombolysis after the standard 4.5-hour time window. In the newly published international EXTEND RCT (EXTending the Time for Thrombolysis in Emergency Neurological Deficits) (Tables 3-6),⁵ when automated CT or magnetic resonance imaging (MRI) perfusion imaging was used in all patients (median NIHSS score range, 10 to 12) to detect hypo-perfused but salvageable regions of the brain, more patients randomized to receive intravenous alteplase up to 9 hours after stroke onset (n=113) had no or minor neurological deficits than those who received placebo (n=112) (35.4% vs. 29.4%; adjusted rate ratio 1.44, 95% CI, 1.01 to 2.06). Symptomatic intracerebral hemorrhage occurred in a nonsignificant greater number of patients in the alteplase group (6.2% vs. 0.9%; adjusted rate ratio 7.22, 95% CI, 0.97 to 53.5). Although EXTEND provides information about the clinical utility of perfusion imaging to guide thrombolysis beyond 4.5 hours in *general*, strong conclusions cannot be drawn about the specific contributions of CTP imaging. This is because patients in the EXTEND RCT received perfusion imaging by either CT or MRI and no information was provided about what proportion received CT, nor were the results stratified by perfusion imaging type. However, a previous systematic review¹ and two previous prospective cohort studies^{6,7} consistently found that use of CTP imaging to select patients for thrombolysis after three hours or 4.5 hours post-acute stroke led to generally favorable outcomes compared to using CTP imaging to select patients for treatment within three hours (Tables 3 and 4)¹ and compared to using NCCT to select patients for treatment within three hours⁷ or 4.5 hours.⁶ In the prospective cohort study by Garcia-Bemejo et al (2012) that compared outcomes between 172 patients treated within 4.5 hours based on NCCT criteria and 43 patients treated after 4.5 hours based on CTP mismatch criteria, there were similar rates of symptomatic intracranial hemorrhagic (2.9% in the <4.5 -hour group vs. 2.3% in the >4.5 -hour group) and good long-term outcome (64.5% vs. 60.5%, respectively) in both groups, supporting further study in a randomized trial. Similarly, a prospective cohort study by Medina-Rodriguez et al (2020) compared 53 patients receiving CTP with 657 control patients receiving standard of care to guide selection of thrombolysis

within 4.5 hours of stroke onset.⁸ The authors found no significant differences between groups at 90 days in symptomatic intracranial hemorrhage (3.8% vs. 3.8%; $p = 1.0$) and mRS < 2 (72.0% vs. 60.4%; $p = 0.107$). These findings support, supporting further study in a randomized trial.

Section Summary: Evaluation for Thrombolysis

Evidence from nonrandomized comparative studies with either concurrent or historical controls has suggested that outcomes after thrombolysis are better in patients who have target mismatch on perfusion imaging than in patients without target mismatch. Evidence from an RCT (EXTEND) and nonrandomized comparative studies also provides general support of the clinical rationale of selecting patients for thrombolysis based on perfusion imaging (MRI or CTP) after a 3 or 4.5-hour time window. The EXTEND RCT had the potential to establish a general clinical rationale of using CTP imaging to select patients for thrombolysis. However, the net health benefit is not clear because the magnitude of improvement on the primary outcome of mRS of 0 or 1 at 90 days was modest and inconsistent between adjusted and unadjusted analyses, there was no significant difference on the secondary outcome of functional improvement, and there was a large increased risk of symptomatic intracranial hemorrhage. Also, the EXTEND RCT had important methodological and relevance limitations, including (1) baseline imbalance in age and NIHSS; (2) indirect intervention – CT or MRI with no stratification; and (3) not an optimal comparator. Therefore, further RCTs are still needed to provide greater certainty whether a strategy employing CTP imaging leads to improved health outcomes compared with traditional treatment strategies for acute stroke.

Evaluation for Mechanical Embolectomy

Review of Evidence

Randomized Controlled Trials

The clinical utility of CTP imaging-based patient selection for thrombectomy has not yet been proven in an RCT in which inclusion of patients was not based on perfusion imaging findings. Numerous RCT's have shown that in patients with ischemic stroke with a proximal cerebral artery or internal carotid artery occlusion that were selected based on having a region of salvageable tissue on CTP imaging, thrombectomy within 6 hours,⁹ at 6 to 16 hours¹⁰ and at 6 to 24 hours¹¹ results in better outcomes than standard medical therapy alone. Also, it should be noted that other comparable trials of mechanical embolectomy from the same period (e.g., Randomized Assessment of Rapid Endovascular Treatment of Ischemic Stroke, Multicenter Randomized Clinical Trial of Endovascular Treatment for Acute Ischemic Stroke in The Netherlands [MR CLEAN], Solitaire with the Intention for Thrombectomy as Primary Endovascular Treatment for Acute Ischemic Stroke) also used time from stroke onset, multiphase CTA, or Alberta Stroke Program Early CT Score to select patients for treatment.¹²⁻¹⁴ Overall, these trials found a significant benefit of mechanical embolectomy with stent retrievers, and generally support a clinical rationale for CTP imaging-based patient selection. However, such studies do not allow any conclusions on whether CTP imaging can reliably differentiate between those who will and won't benefit from thrombectomy.

One of the most recent RCT's that used CTP imaging-based patient selection for thrombectomy -DEFUSE 3 (Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke) by Albers et al (2018), which compared endovascular therapy plus medical therapy (n=92) with medical therapy alone (n=90). DEFUSE 3 enrolled patients with proximal middle-

cerebral-artery or internal-carotid-artery occlusion based on whether their initial infarct volume was ≤ 70 mL, their ratio of volume of ischemic tissue to initial infarct volume was ≥ 1.8 and their absolute volume of potentially reversible ischemia was ≥ 15 mL. Infarct and ischemia parameters were calculated using automated image processing software (RAPID) following selective application of either CTP (73%) or MRI diffusion and perfusion scans (27%). Enrollment was planned for up to 476 patients over 4 years but it was stopped early for efficacy after enrolling 182 patients. DEFUSE 3 was designed to evaluate the effectiveness of endovascular treatment initiated later than the recommended 6 hours after patients were last seen well (6-16 hours) and had the primary outcome of the ordinal score on the mRS at 90 days. Patients were 51% female, had a median age of 70 years, and a median NIHSS score of 16.

Compared to medical therapy alone, thrombectomy improved the 90-day mRS (3 vs. 4; OR 2.77, 95% CI, 1.63-4.70), rate of 90-day functional independence (45% vs. 17%; OR 2.67, 95% CI, 1.60, 4.48) and there were no differences in 90-day death (14% vs. 26%; OR 0.55, 95% CI, 0.30, 1.02) or symptomatic intracranial hemorrhage (7% vs. 4%; OR 1.47, 95% CI, 0.40-6.55).⁹ Furthermore, in a sensitivity analysis based on imaging modality (CT vs. MRI), there was no interaction by modality type in the effects of thrombectomy on 90-day functional independence. However, small sample size, selection bias (CT and MRI selectively used) and potential for residual confounding (no multivariable regression) are major limitations of the subanalysis.

Consistent with DEFUSE 3,¹⁰ the DAWN RCT (DWI or CTP Assessment with Clinical Mismatch in the Triage of Wake-Up and Late Presenting Strokes Undergoing Neurointervention with Trevo)¹¹ and the EXTEND-IA (Extending the Time for Thrombolysis in Emergency Neurological Deficits)⁹ provide evidence that CTP imaging may be useful in identifying people who may benefit from thrombectomy at within 6 hours⁹ and 6 to 24 hours after stroke.¹¹ However, because neither DAWN nor EXTEND-IA involves a comparison of patients who were selected for thrombectomy using other non-CTP imaging approaches or who were not selected for thrombectomy, these RCT's also do not provide definitive evidence of CTP imaging's clinical utility.

Also, findings from two previous nonrandomized studies.¹⁵⁻¹⁶ have raised questions about whether CTP imaging can reliably differentiate between those who will and won't benefit from thrombectomy. First, a subanalysis of data from the MR CLEAN trial by Borst et al (2015) suggests that CTP imaging cannot reliably identify patients who would not benefit from mechanical embolectomy.¹⁵ In this trial, inclusion was not limited to CTP imaging, so investigators could perform it if it were standard procedure at their institution. Of 500 patients in MR CLEAN, 333 (67%) underwent CTP imaging, and 175 (52.6%) had adequate images. Of the 175, 102 fulfilled the CTP mismatch criteria. The primary outcome was the mRS score at 90 days, which was assessed for patients with and without CTP mismatch. There was no significant interaction for mismatch and treatment (mechanical embolectomy or usual care) for the mRS score at 90 days, suggesting that CTP imaging cannot reliably identify patients who would not benefit from mechanical embolectomy. In both treatment groups, there was a shift toward better outcomes in patients who had CTP mismatch compared with those who did not, suggesting a benefit for prognosis.

Second, Rai et al (2013) evaluated rates of recanalization and functional outcomes in a cohort of 99 patients selected by CTP for treatment with endovascular stroke therapy and compared results with historical controls from the MERCI [Mechanical Embolus Removal in Cerebral

Ischemia], Multi-MERCI, and Penumbra device trials that treated all comers.¹⁶ Patients were included if they had anterior circulation symptoms at presentation with a baseline NIHSS score of 8 or greater and intracerebral vascular occlusion on admission CTA correlating with the neurologic deficit. There was no cutoff time for treatment. Successful recanalization was achieved in 55.6%, with a good outcome in 41.4% of patients. The recanalization rate in this study did not differ significantly from the 46% for MERCI and 68% for Multi-MERCI, but was significantly lower than the 82% recanalization rate in the Penumbra trial. In patients who were successfully recanalized, good outcomes were obtained in 67% of patients in this study in comparison with 46% in MERCI, 49% in Multi-MERCI, and 29% in Penumbra. The rate of futile recanalization (defined as a poor outcome despite successful recanalization) was 33% in Rai et al compared with 54% in MERCI, 51% in Multi-MERCI, and 71% for Penumbra.

Further, real-world experience from a high-volume center in the Czech Republic using the automated CTP imaging analysis processing software (RAPID) to select patients for thrombectomy raises questions about the applicability of CTP imaging RCT findings in everyday clinical practice.¹⁷ In the EXTEND-IA RCT⁹ - in which thrombectomy was initiated within a median of 210 minutes post-stroke - rates of 90-day mRS score of 0-2 were 71%. In contrast, in the everyday clinical practice at the Czech Republic center, despite a similar median time from stroke to reperfusion of 230 minutes, rates of 90-day mRS score were much lower at 37%. Czech Republic study authors suggested this may have been due to the somewhat smaller ischemic cores and penumbras in their patients but noted that many other factors that can vary in real-life clinical practice may also play a role (e.g., level/time of successful reperfusion, localization of core and penumbra).¹⁷

Cohort Studies

Results of the CRISP (CT Perfusion to Predict Response to Recanalization in Ischemic Stroke Project) study were published by Lansberg et al (2017).¹⁸ CRISP was a multicenter cohort study of 190 acute stroke patients who were assessed by CTP prior to endovascular therapy, although the decision to proceed with endovascular therapy (stent retrievers, manual aspiration, intra-arterial thrombolytic agents, and/or angioplasty with or without stenting, depending on the operator's preference) was not dependent on the CTP results (automated analysis with RAPID software). Patients up to 18 hours after symptom onset were included. Patients with target mismatch (n=131) had higher odds of a favorable clinical response based on the NIHSS (83% vs. 44%, p=0.002; adjusted OR=6.6; 95% CI, 2.1 to 20.9).

A single-center retrospective cohort study by De Muynck et al (2020) evaluated functional outcomes following introduction of CTP as a selection tool for thrombectomy compared with historical data from a similar local retrospective study.¹⁹ Among patients with acute ischemic stroke who underwent thrombectomy and provided evaluable data, there was no significant difference between CTP-guided selection (n=76) and historical controls (n=65) at 90 days in good functional outcome (mRS score of 0-2; 48.4% versus 44%, respectively; p= 1.0), excellent functional outcome (mRS score of 0-1; 34.4% versus 29%; p = 1.0), and significant ICH (4.1% versus 5%; p= not reported).

Nogueira et al (2021) reported data from a prospective multicenter registry of patients who underwent mechanical embolectomy.²⁰ Patients were included in the study if they had occlusions involving the intracranial internal carotid artery or the M1- or M2-segments of the middle cerebral artery, a premorbid mRS score of 0 to 2, and time-last-seen-well to arterial puncture of 0 to 24 hours. Among patients with time-last-seen-well to arterial puncture of 0 to 6 hours, 332 patients were selected for mechanical embolectomy based on NCCT (with or

without CTA) alone, while 373 also underwent CTP. After adjusting for confounders, there were no differences between patients selected with CTP and patients selected with NCCT with or without CTA in terms of 90-day functional disability (ordinal mRS shift: adjusted OR, 0.936; 95% CI, 0.709 to 1.238 $p=.644$) or independence (mRS 0 to 2: adjusted OR, 1.178; 95% CI, 0.833 to 1.666; $p=.355$). Among patients with time-last-seen-well to arterial puncture of 6 to 24 hours, 68 patients were selected for mechanical embolectomy based on NCCT (with or without CTA) alone, while 180 also underwent CTP. After adjusting for confounders, there were no differences between patients selected with CTP and patients selected with NCCT with or without CTA in terms of 90-day functional disability (adjusted OR, 0.983; 95% CI, 0.81 to 1.662; $p=.949$) or independence (adjusted OR, 0.640; 95% CI, 0.318 to 1.289; $p=.212$). The findings of this study suggest that selection using CTP imaging may not be associated with better outcomes than selection using NCCT with or without CTA alone. This study was a retrospective analysis of registry data and susceptible to selection bias, therefore, findings require confirmation in an RCT.

Subsection Summary: Evaluation for Mechanical Embolectomy

CTP imaging is one of several approaches used in acute stroke to better define viable ischemic tissue that may benefit from mechanical endovascular intervention. One RCT showed improved outcomes with mechanical embolectomy when patients were selected based on CTP imaging results. However, other RCTs have used time from stroke onset, multiphase CTA, and ASPECTS as selection criteria. CTP may be considered an effective method to determine suitability for mechanical embolectomy.

Evaluation for Prognosis

Review of Evidence

Investigators from the Dutch Acute Stroke Trial (DUST; 2017) evaluated prediction models with NCCT, CTA, or CTP at baseline and day 3 to predict the outcome at 90 days.²¹ A total of 224 patients from the DUST trial were selected who had anterior circulation occlusion on CTA with an ischemic deficit on CTP at admission and also had follow-up imaging on day 3. An unfavorable outcome (mRS score of 3-6) at 90 days was identified in 44% of the patients. For models that included baseline variables plus one of the 3 imaging modalities on day 3, the area under the receiver operating characteristics curve was 0.85 for NCCT, 0.86 for CTA, and 0.86 for CTP. All 3 models improved prediction compared with no imaging at day 3, but there was no difference between the models. CTP at day 3 was no better than NCCT in predicting the clinical outcome.

A prognostic model, developed with data from the Dutch Acute Stroke Study (DUST), was reported by van Seeters et al in 2015.²² They analyzed an unselected population of 1374 patients with suspected anterior circulation stroke who underwent multimodal CT. Images were evaluated by an observer blinded to all clinical information except for side of stroke symptoms. The analysis used 60% of patients for a prediction model and 40% for a validation cohort. Poor outcome (90 day mRS score 3-6) occurred in 501 (36.5%) patients. Included in the basic prediction model were patient characteristics (age, stroke severity, time from onset to imaging, dependency prior to stroke symptoms, glucose level, whether treatment had been given) and non-contrast CT measures. CTA and CTP imaging also were predictive of clinical outcome. However, adding CTA and CTP imaging to the basic prediction model did not improve it. For example, in the validation cohort, the area under the curve (AUC) was 0.78 (95% CI, 0.73 to 0.82) when using patient characteristics and NCCT. When CTA and CTP imaging were added to the basic prediction model, the AUC was 0.79 (95% CI, 0.75 to 0.83).

In 2015, Borst et al (discussed above) reported on the relationship between CTP imaging-derived parameters and functional outcomes from the MR CLEAN trial.¹⁵ Functional outcome as measured by mRS score at 90 days was associated with the CTP imaging-derived ischemic core volume (OR=0.79 per 10 mL; 95% CI, 0.73 to 0.87 per 10 mL; p<0.001) and percentage ischemic core (OR=0.82 per 10%; 95% CI, 0.66 to 0.99 per 10%; p=0.002), but not the penumbra. This trial population had been selected for treatment using mechanical embolectomy.

Section Summary: Evaluation for Prognosis

Retrospective analysis of data from the MR CLEAN and DUST trials found that the ischemic core detected on CTP imaging was predictive of functional outcomes. However, analysis of data from the DUST study found no improvement in a prediction model when CTP imaging was added to a basic model that used only patient characteristics and non-contrast CT. CTP at day 3 did not outperform NCCT for stroke prognosis.

SUBARACHNOID HEMORRHAGE AND CEREBRAL VASOSPASM

Clinical Context and Test Purpose

The purpose of CTP imaging in patients with aneurysmal subarachnoid hemorrhage (SAH) is to evaluate those at high risk for vasospasm or delayed cerebral ischemia and to improve treatment decisions.

The question addressed in this evidence review is: Does CTP improve the net health outcome of patients with aneurysmal SAH?

The following **PICOs** were used to select literature to inform this review.

Patients

The relevant population of interest is patients with SAH who are being evaluated for vasospasm or delayed cerebral ischemia.

Interventions

The intervention of interest is CTP imaging as an add-on to NCCT.

Comparators

The following practice is currently being used to make decisions about managing SAH: standard management without CTP.

Outcomes

The outcomes of interest are function measured with NIHSS or mRS scores.

Clinically Valid

A test must detect the presence or absence of a condition, the risk of developing a condition in the future, or treatment response (beneficial or adverse).

Review of Evidence

Cerebral Ischemia

A meta-analysis by Greenberg et al (2010) assessed the diagnostic accuracy of CTA and CTP for cerebral vasospasm identified 3 studies (total n=64 patients) that met the inclusion criteria and contained the appropriate data for statistical analysis.²³ In these studies, "vasospasm" was defined on CTP as a perfusion deficit demonstrating prolonged mean transit time and decreased cerebral blood flow (CBF). However, there were no standardized thresholds for mean transit time or CBF to determine vasospasm, contributing to the heterogeneity among these studies. For this meta-analysis, "angiographic vasospasm" was defined as evidence of arterial narrowing compared with the parent vessel or with a baseline examination; symptomatic and asymptomatic patients were included. Compared with digital subtraction angiography, CTP pooled estimates had 74% sensitivity and 93% specificity.

Cohort Studies

CTP's pattern of sensitivity and specificity with CTP were similar in a retrospective study by Stecco et al (2018) (70% and 100%, respectively). Stecco et al evaluated 19 patients selected for a combined CTA and CTP approach based on clinical signs of arterial vasospasm and positive transcranial Doppler.²⁴ However, given the small sample sizes and the heterogeneity of the CTP imaging data, these results should be considered preliminary.

Sanelli et al (2011) also retrospectively studied the development of vasospasm in 75 patients with the aneurysmal SAH who had a CTP imaging assessment (likely overlap in subjects with the study described above).²⁵ Based on a multistage reference standard, 28 (37%) patients were classified using vasospasm. CTP imaging values (CBF, mean transit time) on days 0 to 3 were significantly lower in the vasospasm group. Optimal thresholds were then determined for CBF (50% sensitivity, 91% specificity), mean transit time (61% sensitivity, 70% specificity), and cerebral blood volume (CBV) (36% sensitivity, 89% specificity). Clinical outcomes of the vasospasm group included 15 (54%) patients with no permanent neurologic deficit, 11 (39%) with the permanent neurologic deficit, and 2 (7%) who died during hospitalization.

Delayed Cerebral Ischemia

A systematic review and meta-analysis by Cremers et al (2014) included 11 studies (total n=570 patients) on the use of CTP to identify delayed cerebral ischemia.²⁶ CTP imaging measures at admission did not differ between patients who did and did not develop delayed cerebral ischemia. Some measures of CTP (CBF and mean transit time but not CBV) differed between groups during the 4 to 14 days after SAH, suggesting a possible role in diagnoses of delayed cerebral ischemia.

A meta-analysis by Sun et al (2019) evaluated the use of CTP to identify patients at risk for delayed cerebral ischemia in the acute phase (<4 days) after aneurysmal SAH.²⁷ The meta-analysis included 3 studies (total n=128 patients), 2 of which were included in the meta-analysis by Cremers et al (2014). The authors reported that patients with positive CTP in the acute phase were significantly more likely to develop delayed cerebral ischemia (OR, 32.15; 95% CI, 9.92–104.21).

Cohort Studies

One study included in the Cremers et al (2014) meta-analysis is the prospective study by Sanelli et al (2011) of 97 patients that evaluated the accuracy of CTP imaging to diagnose delayed cerebral ischemia following aneurysmal SAH.²⁸ CTP imaging was performed between days six and eight in asymptomatic patients and on the day of clinical deterioration in symptomatic patients. Perfusion maps were qualitatively evaluated by two neuroradiologists, both blinded to clinical and imaging data, and compared with the reference standard. Based on

a multistage hierarchical reference standard that incorporated both imaging and clinical criteria, 40 (41%) patients were diagnosed with delayed cerebral ischemia. Overall diagnostic accuracy for CTP, determined from receiver operating characteristic curves, was 93% for CBF, 88% of mean transit time, and 72% of CBV. The study also sought to determine a quantitative threshold for delayed cerebral ischemia with CTP imaging, although it was noted that absolute thresholds might not be generalizable due to differences in scanner equipment and post-processing methods. Clinical outcomes of the delayed cerebral ischemia group included 19 (48%) patients with no permanent neurologic deficit, 16 (40%) with the permanent neurologic deficit, and 5 (13%) who died during hospitalization.

A retrospective cohort study by Staronni et al (2019) of 38 patients with aneurysmal SAH evaluated CTP within 48 hours after hemorrhage.²⁹ The occurrence of DCI was significantly correlated with lower mean early CBF values ($p = 0.049$) and vasospasm with lower mean CBF ($p = 0.01$) and mean transit time ($p < 0.00001$) values. Mean transit time threshold values of 5.5 seconds were shown to have 94% specificity and 100% sensitivity for predicting the risk of developing vasospasm.

Section Summary: Subarachnoid Hemorrhage and Cerebral Vasospasm

One prospective study showed a qualitative measure of cerebral blood flow to have 93% accuracy for the detection of delayed cerebral ischemia, with lower accuracy for cerebral blood volume. RCTs are needed to evaluate whether CTP imaging in patients with aneurysmal subarachnoid hemorrhage leads to the early identification of patients at high risk for vasospasm or delayed cerebral ischemia, alters treatment decisions, and improves health outcomes.

BRAIN TUMORS

Clinical Context and Test Purpose

The purpose of CTP imaging in patients with patients with brain tumors is for grading of gliomas. Potential uses are to guide biopsy and to monitor low-grade gliomas.

The question addressed in this evidence review is: Does CTP improve the net health outcome of patients with brain tumors?

The following **PICOs** were used to select literature to inform this review.

Patients

The relevant population of interest is patients with gliomas.

Interventions

The intervention of interest is CTP imaging as an add-on to NCCT.

Comparators

The comparator of interest is standard management without CTP.

Outcomes

The outcome of interest is glioma grade.

Clinically Valid

A test must detect the presence or absence of a condition, the risk of developing a condition in the future, or treatment response (beneficial or adverse).

Review of Evidence

In 2011, Xyda et al reported a prospective study of the feasibility and efficacy of volume perfusion CT (VPCT) for the preoperative assessment of cerebral gliomas in 46 consecutive patients with suspected cerebral gliomas.³⁰ (Whereas typical perfusion CT covers a relatively narrow range of brain tissue, the VPCT system with multispiral acquisition covers the entire tumor.) Two blinded readers independently evaluated VPCT by drawing volumes of interest (VOIs) around the tumor according to maximum intensity projection volumes. The VOIs were mapped onto the cerebral blood volume, flow, and permeability perfusion datasets, which correspond to histopathologic microvascular density. VPCT was followed by stereotactic biopsy or surgery to evaluate the histopathology of the tumor and classified into low-grade (I and II) and high-grade (III and IV). The diagnostic power of the perfusion parameters were analyzed by receiver operating characteristic (ROC) curve analysis. Permeability demonstrated the highest diagnostic accuracy (97% sensitivity, 100% specificity), positive predictive value (100%), and negative predictive value (94%) to identify or exclude high-grade tumors.

A 2011 review by Jain indicates that most of the literature on the utility of perfusion imaging for glioma grading is based on various MR perfusion techniques.³¹ One study compared CT perfusion with conventional MRI in 19 patients.³² With a cutoff point of greater than 1.92 normalized cerebral blood volume (nCBV), there was sensitivity of 85.7% and specificity of 100% to differentiate high-grade gliomas. There were no significant differences in nCBV between grade III or IV tumors. A subsequent study by Jain and colleagues correlated CT perfusion findings with histopathologic grade in 32 patients with astroglial tumors.³³ Eight additional patients with oligodendrogliomas were excluded from analysis because of the known higher blood volume compared with astroglial tumors. Of the 32 patients included in the study, 8 had low-grade gliomas and 24 had high-grade gliomas. In this selected set of patients, CT perfusion showed significant differences in the grade III and grade IV tumors.

Section Summary: Brain Tumors

For indications such brain tumors, data on CTP imaging are limited. One study assessed the diagnostic accuracy of CTP imaging to differentiate high-grade from low-grade gliomas. Prospective studies in an appropriate patient population are needed to evaluate the sensitivity and specificity of CTP glioma grading, with histopathologic assessment of tumors as the independent reference standard. One prospective study performed ROC analysis to evaluate the diagnostic accuracy of VPCT. This is the first report using VPCT to differentiate gliomas; therefore, replication of these findings in an independent sample is needed. Consistency in the thresholds used is also needed. Studies are also needed to show an improvement in health outcomes with CTP imaging. No recent reports on the use of CTP imaging for the evaluation of brain tumors were identified.

SUMMARY OF EVIDENCE

Acute Stroke

For individuals with acute stroke who are being evaluated for thrombolysis who receive computed tomography perfusion (CTP) imaging, the evidence includes nonrandomized comparative studies. Relevant outcomes are overall survival, test accuracy, symptoms, morbid events, and functional outcomes. One potential area of benefit is greater individualization of

therapy for acute stroke by better defining at risk ischemic areas that may benefit from thrombolysis. Evidence from nonrandomized comparative studies had suggested that outcomes after thrombolysis are better in patients who have target mismatch on perfusion imaging than in patients without target mismatch, and that patients with target mismatch treated after a 3-hour time window have outcomes similar to patients treated within 3 hours. However, the therapeutic changes that would be associated with identifying specific target mismatch pattern on CTP are not well defined. Therefore, randomized controlled trials (RCTs) are needed to determine with greater certainty whether a strategy employing CTP imaging improves health outcomes compared with traditional strategies for the treatment of acute stroke. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals with acute anterior large-vessel stroke who are being evaluated for mechanical embolectomy who receive CTP imaging, the evidence includes a randomized controlled trial. Relevant outcomes are overall survival, test accuracy, symptoms, morbid events, and functional outcomes. CTP is one of several approaches that have been used in acute stroke to better define viable ischemic tissue and therefore may benefit from mechanical endovascular intervention. Alternative methods of patient selection for mechanical embolectomy have included time from stroke onset, multiphase computed tomography angiography, or ASPECTS score. One RCT showed improved outcomes with mechanical embolectomy when patients were selected based on CTP results. The evidence is sufficient to determine qualitatively that the technology results in a meaningful improvement in the net health outcome.

For individuals with acute stroke who are being evaluated for prognosis who receive CTP imaging, the evidence includes retrospective analysis of data from large prospective randomized trials. Relevant outcomes are overall survival, test accuracy, symptoms, morbid events, and functional outcomes. Retrospective analysis of data from the MR CLEAN and DUST trials have found that the ischemic core detected on CTP imaging was predictive of functional outcomes. However, analysis of data from the DUST study found no improvement in a prediction model when CTP imaging was added to a basic model that used only patient characteristics and non-contrast computed tomography. The evidence is insufficient to determine the effects of the technology on health outcomes.

Subarachnoid Hemorrhage

For individuals who have suspected subarachnoid hemorrhage and cerebral vasospasm who receive CTP imaging, the evidence includes a prospective study. Relevant outcomes are overall survival, test accuracy, symptoms, morbid events, and functional outcomes. CTP imaging is being evaluated for the diagnosis of vasospasm and delayed cerebral ischemia following aneurysmal subarachnoid hemorrhage. One prospective study showed a qualitative measure of cerebral blood flow to have 93% accuracy for the detection of delayed cerebral ischemia, with lower accuracy for cerebral blood volume. Prospective trials are needed to determine whether CTP imaging in patients with aneurysmal subarachnoid hemorrhage leads to the early identification of patients at high risk for vasospasm or delayed cerebral ischemia, alters treatment decisions, and improves health outcomes. The evidence is insufficient to determine the effects of the technology on health outcomes.

Brain Tumors

For individuals who have brain tumors who receive CTP imaging, the evidence includes studies on diagnostic accuracy. Relevant outcomes are test accuracy, symptoms, morbid events, and functional outcomes. For indications like brain tumors and head trauma, the data

on CTP imaging are limited. One study assessed the diagnostic accuracy of CTP imaging to differentiate high- grade from low-grade gliomas. Prospective studies in an appropriate population of patients are needed to evaluate the sensitivity and specificity of CTP glioma grading, with histopathologic assessment of tumors as the independent reference standard. One prospective study performed receiver operating characteristic curve analysis to evaluate the diagnostic accuracy of volume perfusion computed tomography (VPCT). This is the first report using VPCT to differentiate gliomas; therefore, replication of these findings in an independent sample of patients is needed as well as clarification of the clinical utility of this information. Studies showing the consistency in the thresholds used are needed as are studies showing improvement in health outcomes with CTP imaging. No recent reports on the use of CTP imaging for the evaluation of brain tumors have been identified. The evidence is insufficient to determine the effects of the technology on health outcomes.

Ongoing and Unpublished Clinical Trials

Some currently unpublished trials that might influence this review are listed in Table 3.

Table 3. Summary of Key Trials

NCT No.	Trial Name	Planned Enrollment	Completion Date
Ongoing			
NCT01387113	Expanding the time window for IV thrombolysis with Rt-PA in acute ischemic stroke patients using computed tomography perfusion imaging: the PERFusion use in stroke evaluation (PERFUSE) study	100	Jan 2022
NCT04879615	Treatment With Intravenous Alteplase in Ischemic Stroke Patients With Onset Time Between 4.5 and 24 Hours	372	Dec 2023
Unpublished			
NCT01923922	CTP in the prognostication of cerebral high grade gliomas	100	Dec 2017 (unknown)
NCT02360670	Penumbra and recanalization acute computed tomography in ischemic stroke evaluation (PRACTISE)	400	Nov 2018

NCT: national clinical trial

SUPPLEMENTAL INFORMATION

Clinical Input Received through Physician Specialty Societies and Academic Medical Centers

While the various physician specialty societies and academic medical centers may collaborate with and make recommendations during this process through the provision of appropriate reviewers, input received does not represent an endorsement or position statement by the physician specialty societies or academic medical centers, unless otherwise noted.

In response to requests, input was received by Blue Cross Blue Shield Association (BCBSA) from 4 physician specialty societies (8 reviewers) and 3 academic medical centers while this policy was under review in 2012. The majority input supported some uses of CTP; however, there was little consensus on the specific indications that would be considered medically necessary. For use in late stroke, most reviewers agreed that CTP can identify patients with late stroke who may benefit from thrombolysis, but there was no consensus on whether the benefits of using this strategy to select patients with late stroke for thrombolysis outweigh the risks. Some additional indications recommended by reviewers included differential diagnosis, e.g. excluding stroke mimics, determination of stroke subtype, determination of stroke extent, identification of patients at high early risk for debilitating stroke following transient ischemic attack, determining the need for blood pressure management, guiding disposition decisions such as the need for intensive care unit placement, and establishing prognosis. Evaluation of chronic cerebral ischemia and head trauma were also noted as potential indications. There was near consensus that CTP is investigational for head trauma and for the staging and management of brain tumors. Additional references were provided, which were subsequently reviewed.

PRACTICE GUIDELINES AND POSITION STATEMENTS

American Heart Association and American Stroke Association

American Heart Association (AHA) and American Stroke Association (ASA) 2012 guidelines for the management of aneurysmal subarachnoid hemorrhage recommend that perfusion imaging with CT or MR can be useful to identify regions of potential brain ischemia (Class IIa; Level of Evidence B). The guidelines state that there are emerging data that perfusion imaging, demonstrating regions of hypoperfusion, may be more accurate for identification of delayed cerebral ischemia than anatomic imaging of arterial narrowing or changes in blood flow velocity by transcranial Doppler. The guidelines concluded that CTP is a promising technology, although repeat measurements are limited by the risks of dye load and radiation exposure.

AHA/ASA's 2013 guidelines for the early management of adults with ischemic stroke recommended that CTP and MRI perfusion and diffusion imaging, including measures of infarct core and penumbra, may be considered for selecting patient for acute reperfusion therapy beyond IV fibrinolytic time windows.³⁴ The guidelines state that these techniques provide additional information that may improve diagnosis, mechanism, and severity of ischemic stroke and allow more informed clinical decision making. (class IIb, level of evidence B)

In 2019, AHA and ASA revised their joint 2018 statement on the use of CTP for the early management of adults with ischemic stroke.³⁵ Table 4 summarizes the new recommendations were made.

Table 4. New Guidelines Recommendations on Use of Computed Tomography Perfusion

Recommendation	SOE	LOB	LOE
In patients eligible for IV alteplase, because benefit of therapy is time dependent, treatment should be initiated as quickly as possible and not delayed for additional multimodal neuroimaging, such as CT and MRI perfusion imaging.	I	Strong benefit	B-NR (nonrandomized)
When selecting patients with AIS within 6 to 24 hours of last known normal who have large vessel occlusion in the anterior circulation, obtaining CTP or DW-MRI, with or without MRI perfusion, is recommended to aid in patient selection for mechanical thrombectomy, but only when patients meet other eligibility criteria from one of the RCTs that showed benefit from mechanical thrombectomy in this extended time window.	I	Strong benefit	A (high quality evidence from multiple RCTs)
In selected patients with acute ischemic stroke (> 16-24 hours of last normal) and large vessel occlusion, DAWN criteria (which may include imaging findings from CTP) may be used for clinical decision making regarding mechanical thrombectomy	Ila	Moderate benefit	B-R (nonrandomized)

CT: computed tomography; CTP: computed tomography perfusion; IV: intravenous; LOC: level of benefit; LOE: level of evidence; MRI: magnetic resonance imaging; RCT: randomized controlled trial; SOE: strength of evidence.

American Society of Neuroradiology et al

In 2013, the American Society of Neuroradiology, the American College of Radiology (ACR), and the Society of NeuroInterventional Surgery issued a joint statement on imaging recommendations for acute stroke and transient ischemic attack patients.³⁶ The following statements were made regarding perfusion imaging:

- “In acute stroke patients who are candidates for endovascular therapy, vascular imaging (CTA, MRA, DSA) is strongly recommended during the initial imaging evaluation. Perfusion imaging may be considered to assess the target tissue “at risk” for reperfusion therapy. However, the accuracy and usefulness of perfusion imaging to identify and differentiate viable tissue have not been well-established.”
- “Determination of tissue viability based on imaging has the potential to individualize thrombolytic therapy and extend the therapeutic time window for some acute stroke patients. Although perfusion imaging has been incorporated into acute stroke imaging algorithms at some institutions, its clinical utility has not been proved.”
- “It is important to note that perfusion imaging has many applications beyond characterization of the penumbra and triage of patients to acute revascularization therapy.... These applications include, but are not limited to, the following: 1) improving the sensitivity and accuracy of stroke diagnosis (in some cases, a lesion on PCT [perfusion CT] leads to more careful scrutiny and identification of a vascular occlusion that was not evident prospectively, particularly in the M2 and more distal MCA branches); 2) excluding stroke mimics; 3) better assessment of the ischemic core and collateral flow; and 4) prediction of hemorrhagic transformation and malignant edema.”

In 2017, the American Society of Neuroradiology, the Society for Pediatric Radiology, and ACR revised their joint practice parameters on the performance of CTP in neuroradiologic imaging.³⁷ The primary indications for CTP imaging of the brain were described as acute neurologic change suspicious for stroke, suspected vasospasm following subarachnoid hemorrhage, and

cerebral hemorrhage with secondary local ischemia. Secondary indications included follow-up of acute cerebral ischemia or infarction, to assist in planning and evaluating therapy effectiveness, in patients with a contraindication to magnetic resonance imaging, in the setting of acute traumatic brain injury, and intracranial tumors. There was “little data” to support a role of brain CTP imaging in pediatric stroke.

American College of Radiology

ACR Appropriateness Criteria, updated in 2016, have provided the following ratings for head CTP imaging with contrast (see Table 5).³⁸

Table 5. Appropriateness of Head Computed Tomography Perfusion Imaging With Contrast

Recommendation	Rating
For asymptomatic individuals with a structural lesion on physical examination (cervical bruit) and/or risk factors	5
If directly employed in decision making and planning treatment for carotid territory or vertebrobasilar transient ischemic attack on the initial screening survey	5
For a new focal neurologic defect, fixed or worsening; less than 6 hours	6
For a new focal neurologic defect, fixed or worsening; longer than 6 hours	5
For evaluation for cerebral vasospasm after aneurismal subarachnoid hemorrhage	5

Ratings of 5 and 6: “may be appropriate”

ACR also noted that CT stroke protocols combining a brain noncontrast CT, CTA, and CTP might produce a relative radiation level of 1 to 10 mSv, and repeated use of this protocol in an individual patient might result in high radiation exposure to the scalp and eyes.

U.S. Preventive Services Task Force Recommendations

Not applicable.

Government Regulations

National/Local:

There is no national coverage determination on this topic.

WPS does have a local coverage determination (LCD): Category III Codes (L35490) Effective on or after 01/01/2022.

CMS considers the concordant level I evidence of a large clinical benefit after CTP imaging (using automated post-processing software algorithmic analysis) in acute ischemic stroke (AIS) secondary to large vessel occlusion (LVO), to assist in late endovascular mechanical thrombectomy (EVT) eligibility determination per AHA/ASA guidelines, medically reasonable and necessary when the following conditions are fulfilled:

1. Intracranial internal carotid artery (ICA) **OR** middle cerebral artery (MCA) occlusion
2. The medical record documents the patient is being considered for endovascular mechanical thrombectomy (EVT) and does not have contraindications to the EVT (based on DAWN or DEFUSE3 trial criteria)
3. Treatment (femoral puncture) can be started within 6-24 hours of the last time known to be at neurologic baseline

While there is a promise to CTP technology applied to other neuroimaging areas, there is still insufficient evidence. Other stroke or non-stroke indications, including routine assessment of AIS, determination of hemorrhagic transformation (HT), and other indications, are not considered medically reasonable and necessary at this time.

(The above Medicare information is current as of the review date for this policy. However, the coverage issues and policies maintained by the Centers for Medicare & Medicare Services [CMS, formerly HCFA] are updated and/or revised periodically. Therefore, the most current CMS information may not be contained in this document. For the most current information, the reader should contact an official Medicare source.)

Related Policies

PET/CT Fusion

References

1. Burton KR, Dhanoa D, Aviv RI, et al. Perfusion CT for selecting patients with acute ischemic stroke for intravenous thrombolytic therapy. *Radiology*. Jan 2015;274(1):103-114. PMID 25243539.
2. Bivard A, Levi C, Krishnamurthy V, et al. Perfusion computed tomography to assist decision making for stroke thrombolysis. *Brain*. Jul 2015;138(Pt 7):1919-1931. PMID 25808369.
3. Schaefer PW, Souza L, Kamalian S, et al. Limited reliability of computed tomographic perfusion acute infarct volume measurements compared with diffusion-weighted imaging in anterior circulation stroke. *Stroke*. Feb 2015;46(2):419-424. PMID 25550366.
4. Liebeskind DS, Parsons MW, Wintermark M, et al. Computed tomography perfusion in acute ischemic stroke: is it ready for prime time? *Stroke*. Aug 2015;46(8):2364-2367. PMID 26159791.
5. Ma H, Campbell BCV, Parsons MW et al. Thrombolysis Guided by Perfusion Imaging up to 9 Hours after Onset of Stroke. *N. Engl. J. Med.*, 2019 May 9;380(19). PMID 31067369.
6. Garcia-Bermejo P, Calleja AI, Perez-Fernandez S, et al. Perfusion computed tomography-guided intravenous thrombolysis for acute ischemic stroke beyond 4.5 hours: a case-control study. *Cerebrovasc Dis*. Jul 2012;34(1):31-37. PMID 22759450.
7. Sztrihai LK, Manawadu D, Jarosz J, et al. Safety and clinical outcome of thrombolysis in ischaemic stroke using a perfusion CT mismatch between 3 and 6 hours. *PLoS One*. Oct 2011;6(10):e25796. PMID 22016775.
8. Medina-Rodriguez M, Millan-Vazquez M, Zapata-Arriaza E, et al. Intravenous Thrombolysis Guided by Perfusion CT with Alteplase in 4.5 Hours from Stroke Onset. *Cerebrovasc Dis*. 2020; 49(3): 328-333. PMID 32615572
9. Campbell BC, Mitchell PJ, Kleinig TJ, et al. Endovascular therapy for ischemic stroke with perfusion-imaging selection. *N Engl J Med*. Mar 12 2015;372(11):1009-1018. PMID 25671797.
10. Albers GW, Marks MP, Kemp S et al. Thrombectomy for Stroke at 6 to 16 Hours with Selection by Perfusion Imaging. *N. Engl. J. Med.*, 2018 Jan 25;378(8). PMID 29364767.
11. Nogueira RG, Jadhav AP, Haussen DC et al. Thrombectomy 6 to 24 Hours after Stroke with a Mismatch between Deficit and Infarct. *N. Engl. J. Med.*, 2017 Nov 14;378(1). PMID 29129157.
12. Berkhemer OA, Fransen PS, Beumer D, et al. A randomized trial of intraarterial treatment for acute ischemic stroke. *N Engl J Med*. Jan 1 2015;372(1):11-20. PMID 25517348.

13. Goyal M, Demchuk AM, Menon BK, et al. Randomized assessment of rapid endovascular treatment of ischemic stroke. *N Engl J Med*. Mar 12 2015;372(11):1019-1030. PMID 25671798.
14. Saver JL, Goyal M, Bonafe A, et al. Solitaire with the Intention for Thrombectomy as Primary Endovascular Treatment for Acute Ischemic Stroke (SWIFT PRIME) trial: protocol for a randomized, controlled, multicenter study comparing the Solitaire revascularization device with IV tPA with IV tPA alone in acute ischemic stroke. *Int J Stroke*. Apr 2015;10(3):439-448. PMID 25777831.
15. Borst J, Berkhemer OA, Roos YB, et al. Value of computed tomographic perfusion-based patient selection for intra-arterial acute ischemic stroke treatment. *Stroke*. Dec 2015;46(12):3375-3382. PMID 26542698.
16. Rai AT, Raghuram K, Domico J, et al. Pre-intervention triage incorporating perfusion imaging improves outcomes in patients undergoing endovascular stroke therapy: a comparison with the device trials. *J Neurointerv Surg*. Mar 2013;5(2):121-127. PMID 22345110.
17. Vanicek J, Cimflova P, Bulik M et al. Single-Centre Experience with Patients Selection for Mechanical Thrombectomy Based on Automated Computed Tomography Perfusion Analysis-A Comparison with Computed Tomography CT Perfusion Thrombectomy Trials. *J Stroke Cerebrovasc Dis*, 2019 Jan 19;28(4). PMID 30655040.
18. Lansberg MG, Christensen S, Kemp S, et al. Computed tomographic perfusion to Predict Response to Recanalization in ischemic stroke. *Ann Neurol*. Jun 2017;81(6):849-856. PMID 28486789.
19. De Muynck E, Huybrechts V, Hemelsoet D, et al. CT Perfusion as a Selection Tool for Mechanical Thrombectomy, a Single-Centre Study. *J Belg Soc Radiol*. Jan 20 2020; 104(1): 3. PMID 31998861
20. Nogueira RG, Haussen DC, Liebeskind D, et al. Stroke Imaging Selection Modality and Endovascular Therapy Outcomes in the Early and Extended Time Windows. *Stroke*. Jan 2021; 52(2): 491-497. PMID 33430634
21. Dankbaar JW, Horsch AD, van den Hoven AF, et al. Prediction of clinical outcome after acute ischemic stroke: the value of repeated noncontrast computed tomography, computed tomographic angiography, and computed tomographic perfusion. *Stroke*. Sep 2017;48(9):2593-2596. PMID 28716981.
21. van Seeters T, Biessels GJ, Kappelle LJ, et al. The prognostic value of CT angiography and CT perfusion in acute ischemic stroke. *Cerebrovasc Dis*. Oct 2015;40(5-6):258-269. PMID 26484857.
22. Greenberg ED, Gold R, Reichman M, et al. Diagnostic accuracy of CT angiography and CT perfusion for cerebral vasospasm: a meta-analysis. *AJNR Am J Neuroradiol*. Nov 2010;31(10):1853-1860. PMID 20884748.
23. Stecco A, Fabbiano F, Amatuzzo P et al. Computed tomography perfusion and computed tomography angiography in vasospasm after subarachnoid hemorrhage. *J Neurosurg Sci*, 2016 Apr 29;62(4). PMID 27124176.
24. Sanelli PC, Jou A, Gold R, et al. Using CT perfusion during the early baseline period in aneurysmal subarachnoid hemorrhage to assess for development of vasospasm. *Neuroradiology*. Jun 2011;53(6):425-434. PMID 20694461.
25. Cremers CH, van der Schaaf IC, Wensink E, et al. CT perfusion and delayed cerebral ischemia in aneurysmal subarachnoid hemorrhage: a systematic review and meta-analysis. *J Cereb Blood Flow Metab*. Feb 2014;34(2):200-207. PMID 24281744.
26. Sun H, Ma J, Liu Y, et al. CT Perfusion for Identification of Patients at Risk for Delayed Cerebral Ischemia during the Acute Phase after Aneurysmal Subarachnoid Hemorrhage: A Meta-analysis. *Neurol India*. Sep-Oct 2019; 67(5): 1235-1239. PMID 31744949

27. Sanelli PC, Ugorec I, Johnson CE, et al. Using quantitative CT perfusion for evaluation of delayed cerebral ischemia following aneurysmal subarachnoid hemorrhage. *AJNR Am J Neuroradiol.* Dec 2011;32(11):2047- 2053. PMID 21960495.
28. Starnoni D, Maduri R, Hajdu SD, et al. Early Perfusion Computed Tomography Scan for Prediction of Vasospasm and Delayed Cerebral Ischemia After Aneurysmal Subarachnoid Hemorrhage. *World Neurosurg.* Oct 2019; 130: e743-e752. PMID 31284055
29. Xyda A, Haberland U, Klotz E, et al. Brain volume perfusion CT performed with 128-detector row CT system in patients with cerebral gliomas: a feasibility study. *Eur Radiol.* Sep 2011;21(9):1811-1819. PMID 21573969.
30. Jain R. Perfusion CT imaging of brain tumors: an overview. *AJNR Am J Neuroradiol.* Oct 2011;32(9):1570-1577. PMID 21051510.
31. Ellika SK, Jain R, Patel SC, et al. Role of perfusion CT in glioma grading and comparison with conventional MR imaging features. *AJNR Am J Neuroradiol.* Nov-Dec 2007;28(10):1981-1987. PMID 17893216.
32. Jain R, Ellika SK, Scarpace L, et al. Quantitative estimation of permeability surface-area product in astroglial brain tumors using perfusion CT and correlation with histopathologic grade. *AJNR Am J Neuroradiol.* Apr 2008;29(4):694-700. PMID 18202239.
33. Connolly ES, Jr., Rabinstein AA, Carhuapoma JR, et al. Guidelines for the management of aneurysmal subarachnoid hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. *Stroke.* Jun 2012;43(6):1711-1737. PMID 22556195.
34. Jauch EC, Saver JL, Adams HP, Jr., et al. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. *Stroke.* Mar 2013;44(3):870-947. PMID 23370205.
35. Powers WJ, Rabinstein AA, Ackerson T, et al. 2018 guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. *Stroke.* Mar 2018;49(3):e46-e110. PMID 29367334.
36. Wintermark M, Sanelli PC, Albers GW, et al. Imaging recommendations for acute stroke and transient ischemic attack patients: A joint statement by the American Society of Neuroradiology, the American College of Radiology, and the Society of NeuroInterventional Surgery. *AJNR Am J Neuroradiol.* Nov-Dec 2013;34(11):E117-127. PMID 23907247.
37. American College of Radiology, American Society of Neuroradiology, Society for Pediatric Radiology. ACR- ASNR-SPR practice parameter for the performance of computed tomography (CT) perfusion in neuroradiologic imaging. 2017; <https://www.acr.org/-/media/ACR/Files/Practice-Parameters/ct-perfusion.pdf?la=en>. Accessed August 5, 2019.
38. American College of Radiology (ACR). ACR Appropriateness Criteria: Cerebrovascular Disease. 2016; <https://acsearch.acr.org/docs/69478/Narrative/>. Accessed August 5, 2019.
39. Blue Cross Blue Shield Association. Computed Tomography Perfusion Imaging of the Brain. Medical Policy Reference Manual. MPRM 6.01.49. Published in 2007. Last updated October 2021.

The articles reviewed in this research include those obtained in an Internet based literature search for relevant medical references through January 2022, the date the research was completed.

Joint BCBSM/BCN Medical Policy History

Policy Effective Date	BCBSM Signature Date	BCN Signature Date	Comments
9/1/09	7/15/09	6/16/09	Joint policy established
7/1/11	4/19/11	5/3/11	Policy reformatted; additional references added.
11/1/12	8/21/12	8/21/12	Routine maintenance; title changed from "Cerebral Perfusion Analysis Using Computed Tomography" to "CT (Computed Tomography) Perfusion Imaging."
11/1/13	8/22/13	8/27/13	Routine review; updated references and rationale.
3/1/15	12/12/14	12/29/14	Routine maintenance; updated references and rationale.
5/1/16	2/16/16	3/16/16	Policy position changed from experimental/investigational to established for select patients with stroke for mechanical embolectomy. All other indications remain experimental/investigational.
5/1/17	2/21/17	2/21/17	Updated rationale section and reference section (adding 3, 15, 18 and 30). No change in policy status.
5/1/18	2/20/18	2/20/18	Updated rationale, added reference # 4, 18, 20 and 31. No change in policy status.
5/1/19	2/19/19		Routine policy maintenance, added reference #27. No change in policy status.
5/1/20	2/18/20		Rationale reorganized, added references 5, 9, 10, 16 and 21. No changes in policy status.
5/1/21	2/16/21		Rationale reorganized and updated, references 8, 19, 26 and 28 added. Government section updated. No change in policy status.

5/1/22	2/15/22		Routine policy maintenance, added reference #20, no change in policy status.
--------	---------	--	------------------------------------------------------------------------------

Next Review Date: 1st Qtr. 2023

BLUE CARE NETWORK BENEFIT COVERAGE
POLICY: CT (COMPUTED TOMOGRAPHY) PERFUSION IMAGING OF THE BRAIN

I. Coverage Determination:

Commercial HMO (includes Self-Funded groups unless otherwise specified)	According to policy guidelines
BCNA (Medicare Advantage)	See government section
BCN65 (Medicare Complementary)	Coinsurance covered if primary Medicare covers the service.

II. Administrative Guidelines:

N/A